Identifying small molecules that are neuroprotective against stroke injury will be highly beneficial for treatment therapies. A cell viability assay and gas chromatography-mass spectrometry were used to identify active small molecules in XingNaoJing, which is a well known Chinese Medicine prescribed for the effective treatment of stroke. Studies have found that muscone is the active compound that prevents PC12 cell and cortical neuron damage following various injuries. Analysis of apoptosis indicated that muscone inhibited glutamate-induced apoptotic cell death of PC12 cells and cortical neurons. Fas and caspase-8 expression were upregulated following glutamate treatment in cortical neurons, and was markedly attenuated in the presence of muscone. Furthermore, muscone significantly reduced cerebral infarct volume, neurological dysfunction and inhibited cortical neuron apoptosis in middle cerebral artery occluded (MCAO) rats in a dose-dependent manner. Moreover, a significant decrease in Fas and caspase-8 expression in the rat cortex was observed in MCAO rats treated with muscone. Our results demonstrate that muscone may be a small active molecule with neuroprotective properties, and that inhibition of apoptosis and Fas is an important mechanism of neuroprotection by muscone. These findings suggest a potential therapeutic role for muscone in the treatment of stroke.
Stroke is a leading cause of death and disability in the world [1] , and involves glutamate excitotoxicity, excessive oxidative stress, free radical production, and apoptosis [2] [3] [4] . Many neuroprotective agents and strategies to combat stroke injury have been investigated [5] . One strategy for achieving neuroprotection is the inhibition of neuronal apoptosis. While peptidic agents like cytokines or neurotrophic factors may be effectively used for the treatment of diseases of the periphery, the prospects for such therapies in the treatment of brain diseases are less promising, simply due to the technical difficulty of getting the agent to the site of injury. Muscone, a small molecule present in XingNaoJing (XNJ) [6] , is one of a hundred traditional Chinese medicinal (TCM) agents used clinically in China for the treatment of stroke, and has approval from the Chinese National Drug Administration [7, 8] . XNJ consists of four Chinese herbs: Moschus, a dry substance secreted by a gland in the sub-umbilical sac of the male musk deer; Radix Curcumae, the tuberous root of the perennial herb Curcuma aromatica Salisb and C. zedoaria (Berg) Rosc., family Zingiberaceae; Fructus Gardeniae, the fruit of Gardenia jasminoides Ellis var. radicans (Thunb.) Makino, family Rubiaceae; and crystals from the evaporated exudate of the trunk of Dryobalanops aromatica Gaertn. f., family Dipterocarpceae. Muscone, which distributes throughout the brain after crossing the blood brain barrier [9] , also has a protective effect in vitro [10] . However, the effect and mechanism of muscone on apoptosis is not clear.
The Fas pathway has been shown to be involved in apoptosis following stroke injury [11] [12] [13] [14] . Fas, which belongs to the tumor necrosis factor (TNF) receptor superfamily, acts as a trigger for apoptosis [15, 16] . Fas initiates intracellular signaling cascades that ultimately terminate in caspase-dependent cell death [17] . Although Fas/FasL was originally characterized in the immune system [18] , Fas and caspase-8 are also expressed throughout the central nervous system [19, 20] , and induce neuronal apoptosis in models of stroke [21] . Neutralizing FasL with antibody treatment or mice with mutant Fas reduced injury after stroke [11, [20] [21] [22] . Therefore, the Fas pathway may provide anti-apoptotic targets. In the present study, we analyzed the small molecules in XNJ and identified those with neuroprotective actions in both in vitro and in vivo stroke models.
Under GC-MS experimental conditions, XNJ was analyzed to obtain the total ion current chromatograms and mass spectra by scanning each chromatographic peak. Results showed that XNJ contained camphor, borneol and muscone.
To investigate which compounds in XNJ had a protective effect on PC12 cells and cortical neurons, five reference compounds were used in dose-response experiments. As shown in Figure 1A , left panel, when PC12 cells were treated with glutamate alone for 72 h, cell viability decreased. However, muscone (S3) (100-300 ng/mL) induced an obvious dose-dependent increase in cell survival of PC12 cells treated with glutamate. However, under the same conditions, the other 4 reference compounds (3-30 µg/mL) had no effect on PC12 cell survival following glutamate-induced injury. These findings suggest that muscone is an active compound in XNJ that has protective properties. We also examined the effects of muscone on cortical neuron damage following glutamate injury. As shown in Figure 1A , right panel, muscone also induced an obvious dose-dependent increase in cell survival of cortical neurons following treatment with glutamate. In order to further characterize the neuroprotective effect of muscone, we used a model of oxidative stress-induced damage by exposing both PC12 cells and cortical neurons to H 2 O 2 (400 µM), a cell permeable oxidant. As can be seen in Figure 1B , muscone protected PC12 cells (left panel) and cortical neurons (right panel) from damage. We also evaluated the effects of muscone on PC12 cells and cortical neurons under serum-free conditions. As shown in Figure 1C , muscone induced an obvious dose-dependent increase in cell survival of PC12 cells (left panel) and cortical neurons (right panel) treated in serum-free conditions. These findings suggest that muscone prevents PC12 cell and cortical neuron damage following various injuries.
The anti-apoptotic effect of muscone on PC12 cells and cortical neurons was verified by flow cytometry. As shown in Figure 2A , PC12 cells treated without glutamate showed minimal Annexin V signal (2%) in quadrant II (Annexin V+/PI−). By comparison, PC12 cells treated with glutamate (100 µM) produced the highest apoptotic population (21%) in quadrant II. In contrast, PC12 cells treated with glutamate in the presence of 100 and 300 ng/mL muscone had reduced apoptotic populations (7% and 4%, respectively). As shown in Figure 2B , cortical neurons treated without glutamate had a minimal apoptotic population (2%), whereas cortical neurons treated with glutamate (100 µM) produced the highest apoptotic population (23%), and 100 and 300 ng/mL muscone reduced the apoptotic population to 6% and 3%, respectively. These results suggest that muscone inhibited apoptosis in PC12 cells and cortical neurons following glutamate injury. Fas was significantly reduced by muscone, and the downstream effector of caspase-8 and caspase-3, which was also induced by glutamate ( Figure 3 ). Figure 4A shows neurological scores after 2 h of MCAO (0 d) and 10 days (10 d) of reperfusion in different experimental groups. There were no significant neurological deficits after 2 h of MCAO (0 d) and reperfusion (10 d) in the different experimental groups. Severe neurological deficits were observed after 10 d of MCAO and reperfusion in MCAO rats treated with vehicle. MCAO rats treated with muscone significantly improved neurological deficits, as evidenced by fewer disturbances in posture and circling movements, p<0.05. MCAO rats treated with muscone had significantly decreased neurological scores, compared with MCAO rats treated with the vehicle.
To address the potential neuroprotective role of muscone in stroke, we examined its ability to reduce infarct volume after MCAO in rats. As shown in Figure 4B , MCAO rats treated with muscone had significantly smaller infarct volumes than vehicle-treated rats after MCAO.
To explore the effects of muscone on apoptosis, TUNEL (TdTmediated dUTP nick end labeling) was used to identify apoptotic cells in the parietal cortex 10 d after MCAO. There was an increase in TUNEL-positive cells in MCAO rats treated with vehicle, whereas brain sections from MCAO rats treated with muscone showed very few TUNEL-positive nuclei. Quantitative analysis of TUNEL-positive cells ( Figure 5A ) revealed that TUNEL-positive nuclei in the ischemic cortex reduced from 35% in MCAO rats treated with vehicle to 20% and 10% in MCAO rats treated with 100 and 300 ng/mL muscone, respectively. These results suggest that the increase in TUNEL-positive cells in the ischemic cortex was inhibited by muscone. In order to further characterize the antiapoptotic effects of muscone, we examined changes in caspase-3 and its substrate poly (ADP-ribose) polymerase (PARP), which are known to play a central role in the execution of apoptosis. The Western blot analysis was performed 10 d after ischemia reperfusion to measure caspase-3 and PARP expression. MCAO rats treated with vehicle showed a robust increase in caspase-3 and PARP in the ischemic cortex. In contrast, caspase-3 and PARP expression was attenuated in MCAO rats treated with muscone ( Figure 5B , left panel). Quantitative analysis revealed that muscone significantly decreased caspase-3 and PARP levels after MCAO compared with MCAO rats treated with vehicle ( Figure 5B , right panel), p<0.05. These results suggest that muscone inhibited neuronal apoptosis induced by cerebral ischemia.
To determine whether the anti-apoptotic activity of muscone correlates with the expression of Fas in a rat MCAO model, we examined the effect of muscone on the expression of Fas and its downstream effector caspase-8 in the ischemic cortex 10 d after MCAO. As shown in Figure 6A and B, real-time RT-PCR assays showed that muscone significantly decreased mRNA expression of Fas and caspase-8 in the ischemic cortex after MCAO compared with MCAO rats treated with vehicle, p<0.05. Western blot analysis demonstrated that muscone significantly decreased the expression of Fas and caspase-8 in the ischemic cortex after MCAO compared with MCAO rats treated with vehicle ( Figure 6C, left panel) . Quantitative analysis revealed that muscone significantly decreased Fas and caspase-8 levels after MCAO compared with MCAO rats treated with vehicle ( Figure 6C, right panel) , p<0.05. These results suggest that muscone inhibited Fas and caspase-8 expression induced by cerebral ischemia. An important finding revealed by the current study is that muscone in XNQ is an active small molecule with neuroprotective properties. To study this neuroprotective effect, we used damage models, which were induced by various challenges such as glutamate, H 2 O 2 and serum-free condition in PC12 cells and neurons of the cortex. Because muscone was effective in protecting PC12 cells and neurons of the cortex in vitro, muscone was selected for further in vivo stroke studies. We found that the compound could significantly protect the brain from damage induced by transient focal cerebral ischemia. This effect occurred in a dose-dependent manner, and the effective dose was similar to that of gambogic amide, a small molecule that possesses robust neuroprotective properties. Consistent with the pharmacological dose of muscone presented here, a prior study in a similar stroke model showed that administration of granulocyte-colony stimulating factor at a dose of 50 μg/kg/day for 3 days had a neuroprotective effect [23] . With regards to the treatment window, our report indicates that muscone treatment began 2 h after reperfusion following MCAO and its effects were maintained for 10 days, which improved functional outcomes. These findings are in agreement with previous studies that indicate neuroprotection is possible within a window of less than 6 h after stroke onset [5] .
The anti-apoptotic action of muscone is one of the proposed mechanisms of neuroprotection. Apoptosis is an important mechanism of cell death in the peri-infarct area after ischemic stroke [24] . PC12 cells impaired by glutamate were used as the cell model of apoptosis [25] . Ischemic stroke causes neuronal death by triggering excess release of glutamate, which is involved in the etiology of ischemic stroke [26, 27] . Therefore, glutamate-induced cell death in cultured PC12 cells represents a useful in vitro model for the study of brain ischemia. In this study, the anti-apoptotic effect of muscone was characterized using flow cytometric analysis. Moreover, the anti-apoptotic effect of muscone was further confirmed in the stroke rat model. These results are consistent with previous findings that both genetic disruption [28] and pharmacological inhibition of caspases are highly neuroprotective in experimental stroke [29] [30] [31] . In agreement with this, the genetic deletion or pharmacological inactivation of PARP reduces cerebral infarct volume after stroke [32, 33] .
An important mechanism revealed by the current study is that the target of the anti-apoptotic effect of muscone is the Fas pathway. Fas, which is commonly categorized as a death receptor because of its well-defined role in apoptosis [34] , has been shown to play an important role in stroke pathogenesis [11] . The expression of Fas and its ligand have been documented in the brain following ischemia [12] . Neutralizing FasL with antibody treatment is associated with neuroprotection in experimental stroke models [20, 22] . This down-regulation of Fas by muscone is a receptor mediated event that occurs in response to apoptosis. We observed a decrease in Fas by muscone, which would provide fewer receptors for FasL to bind to. Consistent with the down-regulation of Fas, we observed the anti-apoptotic effect of muscone. Some reports have shown that treatment with Fas neutralizing antibodies or studying mice deficient in Fas leads to less ischemic injury [20] [21] [22] . Recent work has also shown that estrogen inhibits Fas-mediated apoptosis in experimental stroke. A crucial role of caspase 8 in Fas signaling is observed in caspase 8-deficient mice, which are resistant to Fasinduced apoptosis [35] . Most notably, caspase-8 expression was upregulated by glutamate in cortical neurons, and transient cerebral ischemic injury was markedly attenuated by muscone. These findings are in agreement with previous findings that showed an anti-apoptotic effect of muscone in both in vitro and in vivo stroke models. These results further confirm that the anti-apoptotic effect of muscone may be related to the suppression of the Fas-caspase-8 pathway.
The results of the present study have several important clinical implications. First, muscone may be a potential neuroprotective therapy for ischemic stroke patients. Second, recently, the inhibition of Fas has been shown to protect against central nervous system diseases. Subarachnoid administration of the s-Fas receptor resulted in increased neuronal survival and improved neurologic outcome in an in vivo model of spinal cord injury [22] . Inhibition of Fas-L has also been shown to reduce secondary brain damage in experimental models of brain ischemia [36] . Third, unlike large molecule agents, such as therapeutic antibodies or neurotrophic factors that cannot cross the blood brain barrier [37] , muscone is a small molecule. Therefore, the chances of muscone becoming a therapeutic agent for brain diseases are greater.
Experimental

Animals and materials:
Sprague-Dawley (SD) rats were obtained from the animal centre of Guangzhou University of Chinese Medicine. All animals received humane care in accordance with the guidelines set by the Care of Experimental Animals Committee of Guangzhou University of Chinese Medicine. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), nerve growth factor, Trizol reagent and Annexin V/PI assay kit were purchased from Invitrogen (California, USA); MTT, propidium iodide (PI), Tween-80(0.8%,v/v), dimethyl sulfoxide (DMSO), isoborneol (S1), camphor (S4), and (+)-camphor (S5) were purchased from Sigma (St. Louis, MO, USA); horseradish peroxidase was from New England Biolabs (Hertfordshire, England); Fas antibody, Caspase-8 antibody and the TUNEL detection kit were purchased from Wuhan Boster Biological Technology Co., Ltd. (Wuhan, China). PC12 cells were provided by Shanghai Cellular Institute of China Scientific Academy (Shanghai, China). XingNaoJing injection (batch number, 20091201, 20100203) was bought from Tiandi Pharmaceutical Co., Ltd (Kaifeng, China). (+)-Borneol (S2) and muscone (S3) were from the National Institute for the control of Pharmaceutical and Biological Products (Beijing, China).
Identification of essential components of XNJ:
The GC-MS analysis was performed on a SHIMADZU GCMS-QP5000 gas chromatograph equipped with a mass-selective detector. A DB-1 MS fused-silica capillary column (30m×0.25 mm i.d.) was employed for separation. Electron impact MS were recorded at 70 eV. Ultra-high purity (99.999%) helium was used as the carrier gas at a flow rate of 1 mL/min. The injector and detector temperatures were set at 280°C. The injection volume was 10 μL and all the injections were performed in a split ratio of 1:10. The column temperature was 60°C for 0 min increasing to 280°C in increments of 16°C/min and remaining steady at 280°C for 5 min. The components determined were identified by matching the electron impact (EI) spectra against the NIST library (NIST 98).
Cell culture and viability measurements using the MTT assay:
Cultures of PC12 cells were performed as described previously [38] . Briefly, PC12 cells were grown to confluence in medium containing DMEM (1000 mg/L glucose) supplemented with 5% (v/v) FBS, 10% (v/v) horse serum, and a mixture of 1% (v/v) of penicillin/streptomycin/nystatin. Cell cultures were incubated at 37°C in a humidified 5% CO 2 / 95% (v/v) air environment. PC12 cells were differentiated with 100 ng/mL nerve growth factor for 7 days. Primary cortical cultured neurons were prepared as previously described [39] . Briefly, cortices from 10 to 12 day old fetal rats were dissected, dissociated with trypsin for 4 min at 37°C, triturated with a pipette and then flamed with a glass pipette. The cortical neurons were grown to confluence in neurobasal medium. Cells were then harvested and homogenized for Western blot analysis. Cells were solubilized with lysis buffer, on ice for 30 mins and centrifuged for 10 miNs at 12 000g. The supernatant was then collected, and the concentration of protein quantified. PC12 cells or cortical neuron suspensions (at a cell concentration of 1 ×10 5 / mL) were seeded at 500 cells per well in 96 well plates in serum medium and incubated in 5% (v/v) CO 2 at 37°C for 24 h. PC12 cells or cortical neurons were divided into different groups to investigate drug effects and cell viability. PC12 cells or cortical neurons seeded in serum medium without treatment served as the control, and 5 reference compounds were dissolved in the vehicle (DMSO). An equal volume of DMSO was added to control cultures. For glutamate-induced cell damage, PC12 cells or cortical neurons were incubated with glutamate (100 M) for 6 h, and then cells were treated with or without various concentrations of drugs in fresh
